Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01005485 · ClinicalTrials.gov registry record

Molecular and Morphologic Characterization of Circulating Endothelial Cells

A clinical trial of Acute Myocardial Infarction, sponsored by Scripps Translational Science Institute.

Active
Registry status
664
Enrollment target
1
Study location

NCT01005485 is a study of Acute Myocardial Infarction that is active but no longer recruiting, run by Scripps Translational Science Institute. The registered enrollment target is 664 participants, below the 1,847-participant average among 19 other Acute Myocardial Infarction trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01005485, a study of Acute Myocardial Infarction, is active but no longer recruiting, sponsored by Scripps Translational Science Institute.

ACTIVE NOT RECRUITING
Registry status
664 participants
Enrollment target
1
Study location

Study Summary

The primary hypothesis of this study is that circulating endothelial cells (CECs) harbor key genetic and structural characteristics predisposing individuals to acute atherosclerotic plaque rupture and heart attack.

Study Locations (1)

California

  • Scrippshealth - La Jolla

Trial Details

FieldValue
Enrollment Target 664 participants
Start Date 2010-01
Est. Completion 2025-12

What the Registry Record Tells You About NCT01005485

The ClinicalTrials.gov registry entry for NCT01005485 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 664 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,847-participant average among 19 other Acute Myocardial Infarction trials with a reported enrollment target (64% lower). The listed sponsor is Scripps Translational Science Institute, which has 41 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myocardial Infarction appearing as the primary indexed condition, and to 0 interventions.

NCT01005485 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01005485 about?

NCT01005485 is a clinical study titled "Molecular and Morphologic Characterization of Circulating Endothelial Cells". The primary hypothesis of this study is that circulating endothelial cells (CECs) harbor key genetic and structural characteristics predisposing individuals to acute atherosclerotic plaque rupture and heart attack.

What is the current status of trial NCT01005485?

This trial is currently active not recruiting. The enrollment target is 664 participants. The study started on 2010-01. Estimated completion is 2025-12.

What conditions does trial NCT01005485 study?

This clinical trial studies the following conditions: Acute Myocardial Infarction.

Who is sponsoring clinical trial NCT01005485?

This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01005485 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.